Deerfield Management Company, L.P. (Series C) Myriad Genetics Inc Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Myriad Genetics Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 505 shares of MYGN stock, worth $3,989. This represents 0.0% of its overall portfolio holdings.
Number of Shares
505Holding current value
$3,989% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MYGN
# of Institutions
237Shares Held
95.4MCall Options Held
460KPut Options Held
14.2K-
Black Rock Inc. New York, NY15.2MShares$120 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.26MShares$73.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.92MShares$38.9 Million0.01% of portfolio
-
State Street Corp Boston, MA4.81MShares$38 Million0.0% of portfolio
-
Glenview Capital Management, LLC New York, NY4.59MShares$36.2 Million0.69% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $637M
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...